Immobilized CD27 Protein, Human, Recombinant (His) (Cat#TMPY-03401) at 2 μg/mL (100 μL/well) can bind CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (hFc) (Cat#TMPY-07034), the EC50 is 2-6 ng/mL.

CD27 Ligand/CD70 Trimer Protein, Human, Recombinant (hFc) is expressed in HEK293 Cells. The accession number is P32970-1.

Human

HEK293 Cells

TNLG8A,TNFSF7,LPFS3,CD27LG,CD27-L,CD27L

A DNA sequence encoding the Human CD70(NP_001243.1) (Gln39-Pro193) was expressed with the Fc region of human IgG1 at the N-terminus. This construct has a trimer design.

≥ 90% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC.

Please refer to the lot-specific COA.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy